• Facebook
  • X
  • Events
  • News
  • Donate
Search
Hit enter to search or ESC to close
New Jersey Alliance for Clinical and Translational Science New Jersey Alliance for Clinical and Translational Science
  • Home
  • About
    • Mission
    • Membership
    • Affiliated Institutions
    • NJ ACTS Leadership
    • Cite the CTSA and Publications
    • CTSA Resources
    • Elements
  • Community
    • Our Services
    • Community Leadership
    • Volunteering for a Clinical Trial FAQs
    • Find a Clinical Trial
    • Partnership & Innovation Funding Opportunities
    • COVID-19 Resources
  • Investigator Resources
    • Funding Opportunities
    • Biostatistics, Epidemiology, Research Design (BERD)
    • Informatics Services
    • Regulatory Knowledge & Support
    • Special Populations in Research
    • Team Science
    • Genetically informed Research, Education, And Treatment
    • ResearchMatch (RM)
    • Biomarkers
    • Dissemination & Implementation Workgroup
    • COVID-19
    • Additional Resources
  • Education & Training
    • Workforce Development
    • Badges
    • Seminars, Workshops, Media Library
    • Learning Health System – STAR
    • Promoting STEM in High School and Earlier
    • Undergraduate Education and Training
    • Beyond Traditional Graduate Courses
    • NJ ACTS Collaborative Graduate Programs
  • K12 & T32
    • K12 Mentored Career Development Awards
    • T32 Predoctoral Training Awards
  • Clinical Trials Office
    • About
    • OnCore
    • Solutions
    • Services
    • Manage Studies
    • Resources
  • Contact Us
    • NJ ACTS Newsletter
Select Page
Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients

Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients

by William Jester | May 18, 2020 | Community, Covid, News

Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of...
Researchers Propose Treating COVID-19 Patients With Psoriasis Drug

Researchers Propose Treating COVID-19 Patients With Psoriasis Drug

by William Jester | May 17, 2020 | Community, Covid, News

Scientists are researching if a drug that’s being tested to treat a skin condition can also help keep COVID-19 patients off ventilators. The drug, labeled as EDP1815, was being tested on psoriasis patients, but Dr. Reynold Panettieri, vice chancellor for translational...

Mental Health Providers Face Challenges Adapting to Pandemic

by William Jester | May 16, 2020 | Community, Covid, News

Some community-based mental health providers throughout New Jersey don’t have the funds necessary for the telehealth technology needed to reach patients or the personal protective equipment (PPE) required to protect its staff, according to a Rutgers...

Rutgers Acute Care Surgeon Turns to Hobby for PPE Solutions

by Pamela Dahlen | May 15, 2020 | Community, Covid, News

3D-Printed Face Shields and Eye Shields Provide Help During COVID-19 Pandemic When Joseph S. Hanna purchased his first CR-10 3-D printer roughly four years ago, he never imagined he would one day be using the hobby he loves to have an impact in his chosen profession....
Molecular Beacons Technology Invented by Rutgers Researchers to Be Used in Rapid COVID-19 Tests

Molecular Beacons Technology Invented by Rutgers Researchers to Be Used in Rapid COVID-19 Tests

by William Jester | May 14, 2020 | Community, Covid, News

A recent COVID-19 rapid test that received Food and Drug Administration (FDA) emergency use authorization includes technology invented by Rutgers University researchers, which will be used in about 50,000 tests produced per day by a global health care leader. The...
« Older Entries
Next Entries »

Recent Posts

  • Fighting for Others: How Guilt and Obligation Drives the Desire for More Intensive Treatments in End-of-Life Cancer Care.
  • NJACTS Community Engagement Core COVID-19 Resources
  • Tracking Firearm Violence and Impact on Dental Health.
  • Researchers Investigate How to Integrate Behavioral Health into Primary Care.
  • Scientists map the half-billion connections that allow mice to see.

Archives

  • 2025
    • May
    • April
    • March
    • February
    • January
  • 2024
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2023
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2022
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2021
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2020
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2019
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2018
    • December

Categories

  • Community (2,248)
  • Covid (986)
  • CTO Events (6)
  • News (2,863)
  • Pilots (21)
Rutgers R Block logo graphic

THIS SITE

About

Membership

Community

Investigator Resources

Education & Training

News

Events

Contact

CONTACT US

New Jersey Alliance For Clinical and Translational Science (NJ ACTS)

 


  • Facebook

  • Twitter

  • YouTube

  • LinkedIn

© 2019, New Jersey Alliance for Clinical and Translational Science (NJ ACTS). All rights reserved.| Privacy Policy

Rutgers, The State University of New Jersey, is an equal access/equal opportunity institution. Individuals with disabilities are encouraged to direct suggestions, comments, or complaints concerning any accessibility issues with Rutgers web sites to accessibility@rutgers.edu or complete the Report Accessibility Barrier or Provide Feedback Form.